BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S. as Chief Technology Officer (“CTO”). Mr. Wolfgang brings more than 30 years of biopharmaceutical leadership spanning manufacturing, CMC strategy, development, quality, and supply chain across modalities including cell therapy, b ...

Core Insights - Elicio Therapeutics is presenting new immunogenicity data from its Phase 2 AMPLIFY-7P trial of ELI-002 for mKRAS-driven pancreatic cancer at the SITC Annual Meeting [1] - The company aims to develop off-the-shelf immunotherapies targeting prevalent cancers, leveraging its proprietary AMP technology to enhance T cell responses [3][4] Company Overview - Elicio Therapeutics is a clinical-stage biotechnology company focused on novel immunotherapies for high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers [3] - The company's lead product candidate, ELI-002, targets common KRAS mutations found in approximately 25% of all solid tumors [4][5] - Elicio's AMP technology is designed to improve the education and activation of cancer-specific T cells, promoting durable cancer immunosurveillance [3][7] Clinical Trials and Data - ELI-002 is currently being studied in a randomized clinical trial for patients with mKRAS-positive pancreatic cancer who are at high risk of relapse after standard therapy [3][5] - The AMPLIFY-201 Phase 1 trial data showed a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months for the full study population [3] - Elicio plans to expand ELI-002 to other indications, including mKRAS-positive lung cancer [3] Presentation Details - The late-breaking abstract presentation titled "AMPLIFY-7P Phase 2: T cell responses induced by ELI-002 7P" will be presented by Dr. Lisa McNeil on November 7, 2025 [2] - Another poster presentation titled "AMP-Immunomodulator therapy controls growth and eradicates syngeneic solid tumors" will be presented by Dr. Martin Steinbuck on November 8, 2025 [3]

Core Insights - Elicio Therapeutics has reported preliminary findings from the Phase 2 AMPLIFY-7P trial, indicating that specific Human Leukocyte Antigen (HLA) types do not affect the ability of patients to generate robust mKRAS-specific T-cell responses after treatment with ELI-002 7P [1][3][5] Group 1: Trial Findings - Among 89 patients treated with ELI-002 7P, a total of 1,132 unique HLAs were identified, demonstrating significant genetic diversity within the study population [2][5] - 99% (88 out of 89) of patients assessed for HLA background showed mKRAS-specific T-cell responses post-treatment, suggesting broad applicability of ELI-002 7P for pancreatic ductal adenocarcinoma (PDAC) patients [5][6] - The findings align with recent studies indicating that mKRAS antigens can be presented across a wide range of HLA types, supporting the potential for ELI-002 7P to address a critical unmet need in cancer treatment [2][3] Group 2: Product and Technology Overview - Elicio's lead product candidate, ELI-002, is an off-the-shelf immunotherapy targeting common KRAS mutations, which are responsible for approximately 25% of all solid tumors [4][7] - The AMP technology utilized in ELI-002 aims to enhance the activation and amplification of cancer-specific T cells, potentially leading to durable cancer immunosurveillance [4][9] - Elicio plans to expand the application of ELI-002 to other indications, including mKRAS-positive lung cancer and additional mKRAS-driven cancers, indicating a broad pipeline of therapeutic candidates [6][8]